Results 251 to 260 of about 1,062,704 (335)

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Development of an Escherichia coli Cell-Based Biosensor for Aspirin Monitoring by Genetic Engineering of MarR. [PDF]

Biosensors (Basel)
Kim Y, Jeon Y, Song K, Ji H, Hwang SJ, Yoon Y.   +5 more
europepmc   +1 more source

Genetic Engineering of Drought Resistant Potato Plants by Introduction of the Trehalose-6-phosphate Synthase (TPS1) Gene from Saccharomyces cerevisiae

, 2000
Eun-Taeg Yeo, Hawk-Bin Kwon, Sang-Eun Han, Joon-Tak Lee, Jin-Chang Ryu, Myung-Ok Byun   +5 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Protocol for genetic engineering in Drosophila suzukii using microinjection. [PDF]

STAR Protoc
Yan Y, Schetelig MF.
europepmc   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Genomics, genetic engineering and artificial cells

Annals of Indian Academy of Neurology, 2010
Thomas Sanjeev
doaj  

Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening. [PDF]

Nat Commun
Jin W, Deng Y, La Marca JE, Lelliott EJ, Diepstraten ST, König C, Tai L, Snetkova V, Dorighi KM, Hoberecht L, Hedditch MG, Whelan L, Healey G, Fayle D, Lau K, Potts MA, Chen MZ, Johnston APR, Liao Y, Shi W, Kueh AJ, Haley B, Fortin JP, Herold MJ.   +23 more
europepmc   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Genetic engineering drives the breakthrough of pig models in liver disease research. [PDF]

Liver Res
Xu C, Fang X, Xu X, Wei X.
europepmc   +1 more source